Related Experiment Video

Updated: May 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer

Isabel Heidegger1, Petra Massoner, Iris E Eder

  • 1Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.

The Journal of Steroid Biochemistry and Molecular Biology
|June 25, 2013
PubMed

Insights

New therapies offer hope for advanced prostate cancer. This review details emerging treatments for castration-resistant prostate cancer (CRPC), including novel drugs and immunotherapies, to improve patient survival.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is a significant cause of cancer mortality in men.
  • Castration-resistant prostate cancer (CRPC) has limited treatment options and poor prognosis.

Purpose of the Study:

  • To review novel therapeutic agents for CRPC.
  • To discuss the mechanisms of action for new and investigational drugs.
  • To critically evaluate clinical study results and identify future research needs.

Main Methods:

  • Literature review of recent clinical studies and approved therapies for CRPC.
  • Analysis of drug mechanisms, including hormone synthesis inhibitors, androgen receptor blockers, and immunotherapies.
  • Critical discussion of clinical trial outcomes and limitations.

Main Results:

  • Several new drug classes are available or in advanced clinical trials for CRPC.
  • These agents target various pathways, including hormone synthesis, androgen receptor signaling, angiogenesis, and utilize radiotherapeutics and immunotherapy.
  • Clinical data show promise but highlight limitations and the need for further improvement.

Conclusions:

  • Emerging therapies are expanding treatment options for CRPC.
  • A comprehensive understanding of novel agents and their clinical efficacy is crucial.
  • Continued research is necessary to overcome treatment resistance and enhance survival for CRPC patients.
Keywords:
ARAndrogen receptorBone metastasis angiogenesisCRPCCastration-resistant prostate cancerChemotherapyETGrowth factor receptor inhibitorsIGFImmunotherapyOSPCaPDGFRPFSPSARANK ligandRANK-LRadiotherapySDTKIVEGFVEGFRandrogen receptorcastration-resistant prostate cancerendothelininsulin-like growth factoroverall survivalplatelet-derived growth factor receptorprogression free survivalprostate cancerprostate-specific antigenstable diseasetyrosine kinase inhibitorvascular endothelial growth factorvascular endothelial growth factor receptor

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...